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Abstract Inherited ataxias are heterogeneous disorders
affecting both children and adults, with over 40 different
causative genes, making molecular genetic diagnosis
challenging. Although recent advances in next-generation
sequencing have significantly improved mutation detec-
tion, few treatments exist for patients with inherited ataxia.
In two patients with adult-onset cerebellar ataxia and
coenzyme Q10 (CoQ10) deficiency in muscle, whole exome
sequencing revealed mutations in ANO10, which encodes
anoctamin 10, a member of a family of putative calcium-
activated chloride channels, and the causative gene for
autosomal recessive spinocerebellar ataxia-10 (SCAR10).
Both patients presented with slowly progressive ataxia and
dysarthria leading to severe disability in the sixth decade.
Epilepsy and learning difficulties were also present in one
patient, while retinal degeneration and cataract were
present in the other. The detection of mutations in ANO10
in our patients indicate that ANO10 defects cause sec-
ondary low CoQ10 and SCAR10 patients may benefit from
CoQ10 supplementation.
Keywords Autosomal recessive ataxia  Mitochondrial 
Coenzyme Q10 (CoQ10) deficiency  ANO10
Introduction
Despite major advances in understanding the genetic forms
of ataxia, approximately half of the patients with recessive
ataxia—in particular, adults—do not receive a molecular
diagnosis [1]. Given the numerous etiologies, genetic diag-
nosis requires the performance of a wide range of analyses
and consensus on the diagnostic value of these examinations
is lacking. Recent advances in next-generation sequencing
have significantly improved the mutation detection rate of
inherited ataxias, but treatments for inherited ataxia remain
inadequate. Clinical characterization and evaluation for
A. Balreira and V. Boczonadi joint as first authors.
C. M. Quinzii and R. Horvath contributed equally to this study.
Electronic supplementary material The online version of this
article (doi:10.1007/s00415-014-7476-7) contains supplementary
material, which is available to authorized users.
A. Balreira  E. Barca  M. Hirano  C. M. Quinzii (&)
Department of Neurology, Columbia University Medical Center,
New York, NY, USA
e-mail: cmq2101@cumc.columbia.edu
V. Boczonadi  A. Pyle  B. Bansagi  C. Graham 
H. Lochmu¨ller  H. Griffin  P. F. Chinnery  R. Horvath (&)
Institute of Genetic Medicine, Newcastle University,
Newcastle upon Tyne, UK
e-mail: rita.horvath@ncl.ac.uk
M. Appleton  R. W. Taylor  P. F. Chinnery
Wellcome Trust Centre for Mitochondrial Research, Institute of
Neuroscience, Newcastle University, Newcastle upon Tyne, UK
I. P. Hargreaves
Department of Molecular Neuroscience, UCL Institute of
Neurology, London, UK
V. M. Rasic
Clinic for Neurology and Psychiatry for Children and Youth,
Faculty of Medicine, University of Belgrade, Belgrade, Serbia
A. Naini
Department of Pathology and Cell Biology, Columbia University
Medical Center, New York, NY, USA
123
J Neurol (2014) 261:2192–2198
DOI 10.1007/s00415-014-7476-7
subtle additional features can provide clues to the precise
diagnosis [2].
Coenzyme Q10 (CoQ10) deficiencies comprise a heter-
ogeneous group of autosomal recessive conditions with
primary deficiencies caused by mutations in genes encod-
ing CoQ10 biosynthesis enzymes and secondary forms
caused by genetic defects not directly related to CoQ10
biosynthesis [3].Ataxia is the most common clinical phe-
notype associated with CoQ10 deficiency [3]. The first
causative mutations identified in the ataxic form of CoQ10
deficiency were detected in APTX, which encodes apra-
taxin and is the causative gene for ataxia with oculomotor
apraxia 1 (AOA1) [4]. Reduced CoQ10 levels were reported
in some but not all AOA1 patients with confirmed patho-
genic APTX mutations [4]. Autosomal recessive mutations
in ADCK3, which encodes a kinase involved in CoQ10
biosynthesis, have been identified in several families with
juvenile- or adult-onset ataxia, confirming the link between
ataxia and CoQ10 deficiencies [3, 5]. Some patients
improved on CoQ10 supplementation [3, 5]; the lack of
improvement in some patients has been attributed to the
reduced bioavailability of CoQ10 and its limited ability to
cross the blood brain barrier; however, worsening has been
reported for one patient treated with Idebenone, a short-
chain CoQ analog [6].
In our genetic characterization of a group of patients
with unexplained recessive or sporadic cerebellar ataxia
and low muscle CoQ10, we identified pathogenic mutations
in ANO10 in two families.
Case series
This study had institutional and ethical review board
approval and all the patients gave informed consent.
Patients and methods
We studied 40 unrelated patients with unexplained ataxia
and low CoQ10 in skeletal muscle biopsies without a
dominant family history, in whom well-known genetic
causes of spinocerebellar ataxias (SCA1,2,3,6,7,17,
DRPLA and Friedreich ataxia) and other possible causes of
a progressive ataxia were excluded by clinical and labo-
ratory investigations (brain MRI, CSF analyses, normal
routine biochemistry, blood cell counts, metabolic screen-
ing for acyl-carnitine profiles, urine organic acids, very
long chain fatty acids, phytanic acid, vitamins E, A, B12,
alpha-fetoprotein, serum protein electrophoresis, lipopro-
teins, lysosomal enzymes, copper, ceruloplasmin, ferritin,
iron, and paraneoplastic antibodies).
CoQ10 measurement in plasma, fibroblasts and skeletal
muscle was performed as described [7].
Molecular genetics
Genetic analysis of mitochondrial DNA (mtDNA) for dele-
tions, depletion, and point mutations in muscle DNA as well
as direct sequencing of POLG, PDSS1, PDSS2, COQ2,
COQ9, CABC1/ADCK3 and APTX in blood DNA were
normal in all patients [3]. In patient 1, whole exome
sequencing was performed in genomic DNA, isolated from
lymphocytes (DNeasy, Qiagen, Valencia, CA), fragmented
and enriched by Illumina TruSeqTM 62 Mb exome capture,
and sequenced (Illumina HiSeq 2000, 100 bp paired-end
reads). The in-house bioinformatics pipeline included align-
ment to the human reference genome (UCSC hg19), refor-
matting, and variant detection (Varscan v2.2, Dindel v1.01),
as described previously [8]. On-target variant filtering
excluded those with minor allele frequency greater[0.01 in
several databases. Rare homozygous and compound hetero-
zygous variants were defined, and protein altering and/or
putative ‘disease causing’ mutations, along with their func-
tional annotation, were identified using ANNOVAR [8].
Putative pathogenic variants were confirmed by Sanger
sequencing, using custom-designed primers (http://frodo.wi.
mit.edu) on an ABI 3130XL (Life Technologies, CA, USA),
allowing segregation analyses (Fig. 1a). The primers used for
genomic DNA (NG_028216.1) and cDNA (NM_018075.3)
analysis of ANO10 are listed in the Supplementary Materials
(Supplemental Tables 1 and 2).
To measure ANO10 mRNA expression level, skin
fibroblasts from the patients were grown and total RNA
was extracted using the Pure LinkTM RNA Mini Kit
(Ambion, Life Technologies). RNA concentration was
measured using a Nanodrop. Subsequently, 100 ng of RNA
was converted into cDNA using SuperScript VILO cDNA
Synthesis Kit (Invitrogen). Quantitative RT-PCR (qRT-
PCR) was performed using TaqMan Assays for ANO10 and
GAPDH (Applied Biosystems).
Results
Patient 1 is a 57-year-old English woman who is the second
child of healthy, non-consanguineous parents and has a
healthy brother. After normal early development she
developed generalized epilepsy and learning difficulties at
7 years of age. Her epilepsy was well-controlled, but at age
45 years, she developed gait disturbance, ataxia and slurred
speech. She became wheelchair-bound from age 50 years.
On examination she had slow saccades but no nystagmus,
dysarthria, bilateral dysmetria and a severe trunk ataxia.
Although she had no weakness and deep tendon reflexes were
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normal, she was permanently wheelchair-bound and could
not stand or walk due to severe trunk ataxia and had some
cognitive dysfunction. Brain MRI revealed marked parieto-
occipital and cerebellar atrophy. Nerve conduction studies
and electromyography were normal. Skeletal muscle biopsy
was performed at age 53 years and showed normal histology,
but an isolated complex III deficiency (158 normalize to
citrate synthase, normal mean ± standard deviation
554 ± 345) and low CoQ10 (104 pmol/mg protein, normal
range 140–580). CoQ10 in fibroblasts was normal (147 pmol/
mg protein, normal range 75–190 pmol/mg protein).
Supplementation with 1,000 mg/day CoQ10 had benefi-
cial effects on the patient’s fatigue and mobility within
3–4 months. She was able to stand up and do a few steps
and her cognition has slightly improved. She had no sei-
zures and no epileptic activity on her follow-up EEG,
therefore, antiepileptic medication was slowly withdrawn.
Genetic analysis
Whole exome sequencing detected potentially disease
causing variants in nine genes, but only the variants in
ANO10 segregated with the disease and alter a known
disease gene. Two potentially disease causing variants
(c.132_133insT; p.Asp45Arg fs*53 and c.1843G[A;
p.Asp615Asn) were detected in ANO10 (Fig. 1a), which
were not present in her healthy brother. Unfortunately, both
parents of patient 1 had died and she did not have any
children. One of the detected mutations was a frame-shift
mutation leading to a premature stop codon. The other
mutation c.1843G[A; p.Asp615Asn is a missense change
of a conserved amino acid that has been detected extremely
rarely (rs138000380—1,000 genomes shows only 1 het-
erozygous) and both mutation taster (0.999) and PolyPhen
(0.559) predicted that it is disease causing. cDNA analysis
for ANO10 detected only one allele, which was supported
by the hemizygous state of the c.1843G[A; p.Asp615Asn
change (Fig. 1b).
The detection of pathogenic ANO10 mutations in our
patient with the ataxic form of CoQ10 deficiency promp-
ted us to perform sequencing of ANO10 in 36 further
patients with low CoQ10 in muscle, fibroblasts, or CSF
[3], and we detected pathogenic mutations in one addi-
tional patient.
Fig. 1 Detection of heterozygous ANO10 variants in genomic DNA
of patient 1 (a). cDNA analysis of patient 1 detected the c.1843G[A,
p.Asp615Asn mutation in hemizygous form, confirming compound
heterozygosity (b), Compound heterozygous mutations were detected
in patient 2 (c), Q-RT-PCR showed significantly decreased ANO10
mRNA levels in patient 2’s fibroblast, compared with controls (d).
Values are expressed as mean ± SD of patient and controls (N = 3)
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Patient 2 is a 52-year-old woman with neurologically
normal non-consanguineous parents, and two healthy sib-
lings. At the age of 30 years, she presented with walking
difficulties, slurred speech, and oscilloscopia. The walking
instability progressed slowly and she developed retinal
detachments that were treated with multiple surgeries. At
age 50, because of frequent falls, she started to use a walker
to ambulate long distance. Other ocular problems include:
retinal fibrosis, cataracts, vitreous fluid opacity and possi-
ble macular degeneration. Neurological examination
revealed a stiff-legged wide-based gait with scissoring,
slight eyelid ptosis, primary gaze down-beat nystagmus,
and brisk tendon reflexes with ankle clonus, crossed hip
adductors, and bilateral Hoffmann signs but Babinski signs
were absent. Dysmetria and intention tremor on finger-
nose-finger and heel-to-shin test were present. Brain MRI
revealed marked cerebellar atrophy involving both lobes
and the vermis. Muscle biopsy showed fiber type 2 atrophy.
Respiratory chain complex activities measured in muscle
tissue were normal.
CoQ10 level in the fibroblasts of the patient
(50.6 ± 7.3 nmol/lg protein) was normal (concurrent
controls 48.3 ± 27.8 nmol/lg protein); however, levels of
CoQ10 were decreased in plasma (0.41 lg/ml, normal
range 0.8 ± 0.35 lg/ml) and CSF (410 lg/l, normal range
450–1420 lg/l); and borderline in muscle (21.2 lg/g,
normal range 32 ± 6 lg/g).
CoQ10 supplementation (120–180 mg/day) led to an
initial mild improvement of the ataxia and gait. Evaluation
by the international co-operative ataxia rating scale
(ICAR), showed an improvement in the oculomotor
movement score (from 4/6 to 3/6) and in the dysarthria
score (from 6/8 to 5/8).
Genetic analysis
Direct sequencing of ANO10 in genomic DNA from patient
2 revealed two heterozygous variants, c.132_133insT;
p.Asp45Argfs*53 in exon 2, also present in patient 1, and
c.1315G[T, p.Glu382*, in exon 6 (Fig. 1d). Both variants
generate premature stop codons with truncated protein of
53 aa and 382 aa, respectively (wild-type protein: 660 aa).
The 2 mutations segregated with the disease in the
family (the mother was heterozygous for the
c.132_133insT; p.Asp45Argfs*53 variant, both healthy
siblings were homozygous wild type; and the father’s DNA
was not available) and were not detected in 124 ethnically-
matched control alleles. cDNA analysis showed a signifi-
cant reduction of ANO10 expression level in cultured skin
fibroblast from patient 2 compared to controls (Fig. 1d).
Measurement of CoQ10 in fibroblasts of a previously
published patient (family B, II:5) [9] in carrying pathogenic
ANO10 mutations was normal result (156 pmol/mg pro-
tein, normal range 75–190 pmol/mg protein), however,
muscle was not available for CoQ10 analysis.
Discussion
Anoctamin 10 (ANO10), also known as TMEM16 K, is a
member of the human anoctamin (ANO) family of pro-
teins, which consists of at least nine other proteins, all
containing eight transmembrane domains and a DUF590
domain [9, 10]. It has been suggested that the anoctamin
genes encode cell- and tissue-specific calcium-activated
chloride channels, however, experimental data are limited
[10]. The clinical presentations of mutations in the various
Fig. 2 Schematic representation of ANO10. In green: putative intra-cytoplasmic region, in blue: putative transmembrane domains, in orange:
putative extracellular domains. Text in red: previously reported mutations; in bold italic: mutations found in our patients
J Neurol (2014) 261:2192–2198 2195
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anoctamin genes are very heterogeneous, and include limb-
girdle muscular dystrophy (ANO5), skeletal abnormalities
(Gnathodiaphyseal dysplasia due to ANO5 mutations),
blood cell disorders (Scott syndrome caused by ANO6
defects), as well as progressive neurological presentations
of autosomal dominant dystonia (DYT24 due to ANO3
mutations) and cerebellar ataxia and atrophy (ANO10
defects) [10].
Mutations in ANO10 (Fig. 2) has been associated with
autosomal recessive cerebellar ataxia in only five families
[9, 11, 12]. The clinical presentation of the previously
reported patients showed cerebellar ataxia and atrophy
with variable age-at-onset between 13 and 45 years, brisk
reflexes, and eye movement abnormalities. Additional
features included: intellectual deficit, motor neuron
involvement and epilepsy in some but not all patients,
illustrating the significant clinical variability (Table 1).
Although the clinical presentation of our patients resem-
bles the previously reported cases, and confirms the
clinical phenotype of ANO10 deficiency, muscle biopsies
and measurement of CoQ10 have never been assessed
before in this condition. Because 2 out of 40 patients
(5 %) from our cohort carried mutations in ANO10, we
suggest that defects in this gene should be considered in
patients with unexplained ataxia and low CoQ10 in skel-
etal muscle.
The low CoQ10 levels and the beneficial effect of CoQ10
supplementation in our patients carrying ANO10 mutations
are unexpected findings and raise the question whether low
CoQ10 contributes to the disease pathomechanism, poten-
tially by affecting CoQ10 dependent functions, which was
supported by slightly low CoQ10 in fibroblasts of a previ-
ously reported patient [9]. Interestingly, in one of our
patients, seizures disappeared after CoQ10 supplementa-
tion, as previously reported in a patient with CoQ10 defi-
ciency and cerebellar ataxia due to APTX mutations [4]. It
has been postulated that cerebellar ataxia in patients with
ANO10 deficiency may be due to abnormal calcium sig-
naling in Purkinje cells [10]. Calcium signaling has been
shown to be important for mitochondria, and this year,
mutations in the gene encoding for the mitochondrial cal-
cium uptake 1 (MICU1) protein have been identified in
some families with proximal myopathy, learning difficul-
ties and a progressive extrapyramidal movement disorder
[13]. The role of ANO10 and CoQ10 in calcium signaling
need to be further investigated. Functional studies in
additional patients or animal models will be helpful to
characterize the pathomechanism of ANO10 mutations and
will define the role of CoQ10 deficiency in ANO10-related
disease. The observations of low CoQ10 levels and the
beneficial effect of high-dose CoQ10 supplementation in
our patients suggest that CoQ10 should be considered in the
therapy of ANO10 deficiency.
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